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Summary
Background: Mad1 and Mad2 are constituents of the
spindle-assembly checkpoint, a device coupling the
loss of sister-chromatid cohesion at anaphase to
the completion of microtubule attachment of the sister
chromatids at metaphase. Fluorescence recovery after
photobleaching (FRAP) revealed that the interaction of
cytosolic Mad2 with kinetochores is highly dynamic,
suggesting a mechanism of catalytic activation of Mad2
at kinetochores followed by its release in a complex with
Cdc20. The recruitment of cytosolic Mad2 to kineto-
chores has been attributed to a stable receptor com-
posed of a distinct pool of Mad2 tightly bound to
Mad1. Whether specifically this interaction accounts
for the kinetochore dynamics of Mad2 is currently un-
known.
Results: To gain a precise molecular understanding of
the interaction of Mad2 with kinetochores, we reconsti-
tuted the putative Mad2 kinetochore receptor and de-
veloped a kinetochore recruitment assay with purified
components. When analyzed by FRAP in vitro, this sys-
tem faithfully reproduced the previously described in
vivo dynamics of Mad2, providing an unequivocal mo-
lecular account of the interaction of Mad2 with kineto-
chores. Using the same approach, we dissected the
mechanism of action of p31comet, a spindle-assembly
checkpoint inhibitor.
Conclusions: In vitro FRAP is a widely applicable
approach to dissecting the molecular bases of the inter-
action of a macromolecule with an insoluble cellular
scaffold. The combination of in vitro fluorescence
recovery after photobleaching with additional fluores-
cence-based assays in vitro can be used to unveil mech-
anism, stoichiometry, and kinetic parameters of a
*Correspondence: andrea.musacchio@ifom-ieo-campus.itmacromolecular interaction, all of which are important
for modeling protein interaction networks.
Introduction
Fluorescence recovery after photobleaching (FRAP) is
an imaging technique that takes advantage of the fact
that fluorophores can be irreversibly photobleached
within a given area by using a focused beam of light
[1, 2]. If biological molecules containing bleached fluoro-
phores leave the area, they will be replaced with
nonbleached fluorescent molecules. This allows kinetics
measurements and the determination of the fraction of
recovery, which can reveal the existence of a spatially
fixed, immobile fraction of the ligand that cannot be re-
placed with ligand bound to unbleached fluorophores
from solution [1, 2].
Among FRAP’s several insightful applications is the
possibility of studying the kinetics of binding of macro-
molecules to various cellular compartments and organ-
elles [1, 2]. A limitation of these studies, however, is that
the relationship between the kinetic FRAP measure-
ments and the specific molecular interactions on which
they are based usually remains unknown. This is be-
cause in most cases the identity of the macromolecules
involved and their regulation are not known in sufficient
detail. A possible strategy to overcome this limitation
consists in (1) making an assumption about the identity
of the molecular players in the interaction, (2) reconsti-
tuting the interaction in vitro with purified components,
(3) measuring the dynamic properties of this reconsti-
tuted system, and (4) assessing their similarity with
values determined in vivo [2]. Arguably, this approach
would have widespread beneficial consequences on
our ability to model complex biological systems [3, 4].
Here, we provide an account of our attempts to apply
this strategy to the study of the interaction of the spin-
dle-assembly checkpoint (SAC) protein Mad2 with kinet-
ochores, because this has been extensively investigated
by FRAP in vivo [5–8]. Kinetochores are complex protein
scaffolds that assemble on centromeric DNA. They me-
diate the attachment of microtubules during mitosis and
recruit the SAC proteins to monitor this process [9]. For
coordinating the onset of anaphase with the completion
of the attachment process, Mad2 is believed to be acti-
vated at unattached kinetochores to sequester Cdc20,
its target in the checkpoint [10, 11]. Mad2 has two stable
conformations differing for the position of a 50 residue
segment at its C terminus [12, 13]. The closed conforma-
tion (C-Mad2) is observed when Mad2 binds Cdc20 [12,
13]. C-Mad2 is also observed in the complex of Mad2
with Mad1, a SAC protein that is necessary for Mad2 ki-
netochore recruitment [13–18]. The open conformation
of Mad2 (O-Mad2) is the physiological state of cytosolic
Mad2 in the absence of Mad1 or Cdc20 [19, 20].
As summarized in Table 1A–1E, FRAP experiments on
Mad2 provided apparently conflicting results. Two stud-
ies (Table 1B and 1C) using either transient transfection
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757Figure 1. Mad2 and Its Biochemistry
(A) Elution profile of Alexa-Mad2wt from a Superdex 200 PC 3.2/30 size-exclusion chromatography (SEC) column. SDS-PAGE and Coomassie
staining of the content of fourteen 50 ml fractions eluting between 1.10 and 1.80 ml are shown. Traces were recorded at 280 nm and 495 nm
are black and green, respectively.
(B) Profile of unlabeled Mad1:Mad2. Absorbance at 495 nm was not observed because the complex is unlabeled.
(C) Alexa-Mad2wt was mixed with stoichiometric amounts of unlabeled Mad1:Mad2 and incubated for 1 hr prior to SEC. Most Alexa-Mad2 signal
eluted with the Mad1:Mad2 complex, which was shifted toward higher molecular weights upon binding Alexa-Mad2.
(D) Schematic representation of the interaction of O-Mad2 (red square) with C-Mad2 bound to the C-terminal domain of Mad1 (yellow circles and
gray rectangle, respectively).of GFP-Mad2 or direct injection of Alexa-fluor-488-la-
beled Mad2 in live cells prior to mitosis reported near
to 100% recovery of Mad2 kinetochore fluorescence [5,
6]. Another study (Table 1A) exploiting stable cell lines
expressing YFP-Mad2 revealed instead that the rapidly
exchanging pool of Mad2 accounts forw50% of kineto-
chore Mad2, whereas another w50% resides stably at
these structures [7]. All studies, on the other hand, found
that Mad1 is mainly a stable kinetochore resident in mito-
sis [5, 7]. These observations led to the hypothesis that
a complex of Mad1 with Mad2 (Mad1:Mad2), accounting
for the immobile Mad1 and Mad2 fractions, might be re-
sponsible for the recruitment of a mobile fraction of
Mad2 from the cytosol [7]. The ‘‘Mad2 template’’ hypoth-
esis [19] tried to provide a more detailed molecular de-
scription of this reaction by proposing that the cytosolic
fraction of Mad2, which adopts the O-Mad2 conforma-
tion, is recruited to the kinetochores by the C-Mad2 con-
former in the Mad1:C-Mad2 complex. According to the
‘‘Mad2 template’’ model, the ability of O-Mad2 to form
a conformational dimer with C-Mad2 is the critical inter-
action for kinetochore recruitment of cytosolic O-Mad2.
The significance of the model will be discussed thor-
oughly later in this paper.We reasoned that if the molecular description of the
Mad2 kinetochore cycle provided by the ‘‘Mad2 tem-
plate’’ model were correct, a system of purified compo-
nents and defined composition containing O-Mad2 and
the Mad1:C-Mad2 complex should display dynamic
properties comparable to those observed in living cells.
Ideally, this system might also provide a convincing ex-
planation for the discrepancies in recovery efficiencies
in different experiments that we have detailed above.
Here we provide an account of our findings.
Results
The binding of Mad2 to the Mad1:Mad2 complex can be
visualized by using size-exclusion chromatography
(SEC). Recombinant wild-type human Mad2 (Mad2wt)
was covalently labeled with Alexa-fluor-488 (abbrevi-
ated as Alexa, Figure 1A). When stoichiometric amounts
of Alexa-Mad2 and the unlabeled recombinant Mad1:
Mad2 complex (whose elution profiles are shown in Fig-
ures 1A and 1B, respectively) are mixed, the Alexa-Mad2
signal is incorporated in a high-molecular complex with
Mad1:Mad2 (Figure 1C). Identical results were obtained
Current Biology
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(A) Biotin-Mad1:CFP-Mad2 was immobilized on streptavidin beads. CFP-Mad2 fluorescence remained limited to the surface of the beads. There
was no significant loss of CFP-Mad2 fluorescence in the prebleaching phase (see graph), indicating that the Mad1:CFP-Mad2 complex does not
significantly dissociate and is stably bound to the beads. After bleaching (shown schematically with the appearance of a black CFP hexagon), no
recovery is observed. The white bar in the upper left corner of the first panel indicates 10 mm.
(B) As in (A), but with 15 mM CFP-Mad2 added to the medium. After an equilibration phase, bleaching was carried out and recovery monitored.
The recovery curve is one of 17 equivalent curves. The statistics on this dataset are described in Table 1F.if CFP-Mad2 was used instead of Alexa-Mad2 (Figures
S1A and S1B in the Supplemental Data available online).
Our recently formulated ‘‘Mad2 template’’ hypothesis
[19] suggests that the binding reaction causing the shift
of Alexa-Mad2 consists of the binding of O-Mad2
(drafted from the Alexa-labeled population) to a stable
C-Mad2 conformer in the Mad1:Mad2 complex (Figure
1D). The hypothesis predicts that the two populations
of Mad2 shown in Figure 1D do not exchange subunits,
because C-Mad2 does not dissociate from Mad1. Con-
sequently, the ‘‘Mad2 template’’ model predicts that
the kinetochore cycle of Mad2 is caused by the binding
of O-Mad2 to the C-Mad2 subunits contained in the
Mad1:Mad2 complex.
We tested this prediction by using a strategy of in vitro
FRAP. For this, we reconstituted a fluorescent version of
the Mad1:C-Mad2 kinetochore complex by bacterial co-
expression of CFP-Mad2 and biotinylated Mad1 and im-
mobilized it on streptavidin beads. Beads containing
Mad1:CFP-Mad2 were brightly fluorescent when im-
aged with a confocal microscope. Although the complex
is noncovalent, fluorescence intensity remained con-
stant in the absence of soluble CFP-Mad2 (Figure 2A).
Thus, the Mad1:Mad2 tetramer is sturdy, and the rate
of dissociation of CFP-Mad2 from Mad1 is negligible
[12, 21]. After CFP bleaching in a small area, no recovery
of fluorescence was observed, showing that theimmobilized sample does not undergo lateral diffusion
at the beads’ surface (Figure 2A; see Figures S1 and
S2 for additional controls).
Checkpoint response requires both kinetochore-
bound and cytosolic Mad2 [17]. To analyze the interac-
tion of ‘‘cytosolic’’ Mad2 with ‘‘kinetochores,’’ we added
CFP-Mad2 to the medium containing the Mad1:CFP-C-
Mad2 beads. In the presence of soluble CFP-Mad2, we
observed rapid recovery of 38%6 5% of the prebleach-
ing fluorescence (Figure 2B and Table 1F). The time-de-
pendency of the recovery was nicely fitted with a single
exponential function (1 2 e2kt) with a recovery half-
time (t1/2) of 4.2 s. As in living cells [5–8], there is there-
fore a single type of Mad2 binding site on our in vitro
‘‘kinetochores.’’
Since CFP-C-Mad2 does not dissociate from Mad1
(Figure 2A), thew40% recovery observed in this exper-
iment must be due to CFP-O-Mad2 cycling between so-
lution and Mad1:C-Mad2. If CFP-O-Mad2 replaced
bleached CFP-C-Mad2 directly bound to Mad1, near
to full recovery would be predicted. To confirm this,
we applied two consecutive rounds of photobleaching
to the same area of the beads (Figure 3A and Table
1M). Whereas the first photobleaching was followed by
w40% recovery, the second event resulted in 75% 6
5% recovery, about twice the value observed after the
first photobleaching. The half-time of recovery for the
Spindle-Checkpoint Dynamics In Vitro
759Figure 3. Further Characterization of Mad2 Dynamics In Vitro
(A) Serial photobleaching of CFP-Mad2 in vitro. Two consecutive photobleaching events were imposed on the same area. Recovery after the first
photobleaching event isw38%6 5%. After the second event, recovery approachesw75%6 5%. Statistics for this experiment are in Table 1M.
(B) If C-Mad2 is unlabeled, recovery approachesw87%6 8% of the initial fluorescence already after the first bleaching event. See Table 1G for
statistics.
(C) Recombinant Mad1:CFP-Mad2 was IPed with an anti-Mad1 monoclonal antibody (shown in orange in the scheme on the left) bound to pro-
tein-G on beads (light green circle). There is no significant lateral diffusion of the Mad1:CFP-Mad2 complex on the beads.
(D) Western blotting of Mad1 IP beads from mitotic HeLa-cell extracts with anti Mad1 and anti Mad2 antibodies.
(E) HeLa Mad1 IP beads incubated with 2 mM CFP-Mad2 became brightly fluorescent (left). Addition of Cdc20111–138 at 40 mM caused a rapid
release of fluorescence from beads (right).
(F) FRAP experiments were carried out with HeLa Mad1 IP beads in the presence of 15 mM CFP-Mad2. Recovery was 75% 6 8% (Table 1H).
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760Figure 4. O-Mad2DC Cycles at Kinetochores
(A) Elution profile of Alexa-Mad2DC from a Superdex 200 PC 3.2/30 column.
(B) Alexa-Mad2DC was mixed with stoichiometric amounts of Mad1:Mad2 and incubated for 1 hr. Most Alexa-Mad2DC signal eluted with the
Mad1:Mad2 complex, which was shifted toward higher molecular weights upon binding Mad2.
(C) Alexa-Mad2DC was analyzed by FRAP at the surface of beads containing Mad1:C-Mad2.
(D) Alexa-Mad2 was introduced by injection in PtK1 cells and found to localize at kinetochores as described previously [5, 6]. The FRAP exper-
iment shown here reveals that Alexa-Mad2DC, like Mad2wt, cycles rapidly at unattached kinetochore in PtK1 cells. Quantification of this exper-
iment is reported in Table 1E.second event (4.6 s), however, was essentially identical
to that of the first event, indicating that recovery is due to
the same binding reaction. Thus, the Mad1-bound CFP-
C-Mad2 fraction bleached after the first laser pulse can-
not be replaced with fluorescent CFP-Mad2. The sec-
ond FRAP experiment is analogous to carrying out an
experiment with beads containing dark biotin-Mad1:C-
Mad2 and soluble CFP-Mad2. This experiment resulted
in 87% 6 8% fluorescence recovery (Figure 3B and Ta-
ble 1G). The use of Alexa-Mad2 rather than CFP-Mad2 in
the soluble pool did not change significantly the fraction
and half-time of recovery (Table 1J).
Next, we asked whether the Mad1:Mad2 complex iso-
lated from HeLa cells is capable of binding fluorescent
Mad2 like its recombinant counterpart. For this, we im-
mobilized a monoclonal anti-Mad1 antibody onto proteinG-Sepharose beads and immunoprecipitated the
Mad1:Mad2 complex from mitotic HeLa cell extracts
(see Experimental Procedures). As a positive control,
we first carried out an immunoprecipitation (IP) on the re-
combinant Mad1:CFP-Mad2 complex. Beads bound to
the IPed recombinant Mad1:CFP-Mad2 were used in
a control FRAP experiment to show that there is no sig-
nificant lateral diffusion of the fluorescent protein
(Figure 3C), presumably because the anti-Mad1 mono-
clonal antibody binds tightly to Mad1.
Both Mad1 and Mad2 were present in the HeLa IPs
(Figure 3D). Upon incubation of the Mad1:Mad2 contain-
ing beads with recombinant CFP-Mad2, the beads be-
came fluorescent, indicating that CFP-Mad2 recognizes
the precipitated complex (Figure 3E). Binding of CFP-
Mad2 to the beads was specific, because the addition
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761Figure 5. p31comet Interferes with the O-Mad2:C-Mad2 Interaction
(A) Biotin-Mad1:Mad2 was incubated with 15 mM CFP-Mad2wt (upper panel). After equilibration, Mad2DC (30 mM) was added (lower panel). After
50, most of the CFP-Mad2 fluorescence had dissociated from the beads.
(B) Elution profile of CFP-p31comet from a Superdex 200 PC 3.2/30 SEC column. SDS-PAGE and Coomassie staining of the content of fourteen 50
ml fractions eluting between 1.10 and 1.80 ml. Traces recorded at 280 nm and 458 nm are black and cyan, respectively.
(C) CFP-p31comet and Mad1:C-Mad2 were mixed stoichiometrically and analyzed as above. p31comet was incorporated in the high-molecular-
weight complex with Mad1:Mad2.
(D) CFP-p31comet was added to a medium containing biotin-Mad1:Mad2 bound to streptavidin beads. The FRAP behavior of CFP-p31comet is
displayed. The dataset is described in Table 1L.
(E) CFP-Mad2 (15 mM) was incubated with biotin-Mad1:Mad2 (upper panel). After equilibration, unlabeled CFP-p31comet was added (15 mM). CFP-
Mad2 fluorescence dissociates from the beads (lower panel), indicating that p31comet competes with O-Mad2 for binding C-Mad2.of synthetic peptide encompassing the Mad2 binding
region of Cdc20 (Cdc20111–138) caused the dissociation
of CFP-Mad2 fluorescence from the beads. This con-
firms that C-Mad2 created upon binding to Cdc20111–138
is unable to bind the C-Mad2 contained in the Mad1:
Mad2 IPs. To avoid overinterpretations, however, we
wish to clarify that this experiment does not necessarily
imply that the binding of O-Mad2 to Cdc20111–138 re-
quires, or is facilitated by, the Mad1:Mad2 complex on
the beads, because it has been shown before that this
interaction advances also in the absence of Mad1:Mad2in vitro [12, 13, 19]. This issue will be discussed more
thoroughly later.
An in vitro FRAP experiment was carried out with
Mad1 IPs in the presence of CFP-Mad2 (Figure 3F). Re-
markably, the t1/2 and percent recovery (3.5 6 1.1 s and
75%6 8%, respectively; see Table 1H) were very similar
to those measured with the recombinant Mad1:C-Mad2
complex (Table 1G). Overall, these observations are
completely consistent with the hypothesis that a stable
Mad1:C-Mad2 kinetochore complex accounts for the
observed immobile fractions of Mad1 and Mad2 [7, 19].Table 2. Dissociation Constants
Row Method Reaction KD DG DH TDS
Comments and
Reference
A ITC O-Mad2 + Mad1-bound
C-Mad2
0.95–1.12 mMa 28.1 kcal/mol 25.5 kcal/mol 2.6 kcal/mol This study
B ITC p31comet + Mad1-bound
C-Mad2
25 nMa 210.4 kcal/mol 211.0 kcal/mol 20.6 kcal/mol This study
a Two independent measurements gave very similar results. Average values are reported.
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762Figure 6. The Dissociation of O-Mad2 from Mad1:C-Mad2 Is Not Affected by Cdc20
(A) Mad1:C-Mad2 was immobilized at the bottom of a 25 ml flow chamber attached to a peristaltic pump. Left panel: the glass surface of the flow
chamber. Middle panel: CFP-Mad2 binds the Mad1:C-Mad2 surface. Right panel: the addition of a synthetic peptide corresponding to the Mad2
binding site of Cdc20 (residues 111–138) generates the C-Mad2 version of CFP-Mad2, which is unable to bind the surface.
(B) A FRAP experiment on the flat substrate. Dark Mad1:C-Mad2 and free CFP-Mad2 were used. The experiment is conceptually identical to that
shown in Figure 3B. Statistics for this experiment are in Table 1N.
(C) CFP-Mad2 (2 mM) was allowed to equilibrate on the Mad1:C-Mad2 substrate. A solution containing 40 mM O-Mad2DC (or Mad2wt, Table 1O)
was flowed in the chamber and the dissociation of CFP-Mad2 monitored. The dissociation rates in the presence of 40 mM dark Mad2wt were
essentially identical (data not shown). The dataset is described in Table 1P.
(D) The same reaction using all of the above and 40 mM Cdc20111–138 peptide. The dataset is described in Table 1Q. Mad2DC was used as
dark O-Mad2 in this experiment because this mutant binds Mad1:C-Mad2 but is unable to bind Cdc20, and therefore will not deplete Cdc20
in solution [19].
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recruitment of a mobile fraction of O-Mad2 from the
cytosol. We suspect that the w10%–20% deviation of
the observed recovery values from the expected values
in different experiments (see Table 1) is caused by photo-
damage of the receptor-ligand complexes by the high
laser power required for photobleaching. We are pres-
ently exploring strategies to limit this effect.
Mad2DC is a Mad2 deletion mutant stably locked in the
O-Mad2 conformation and unable to bind Mad1 or
Cdc20 [19]. Previously, we have shown that this mutant
is able to localize to the kinetochore upon injection in
PtK1 cells [19]. In agreement with the hypothesis that
the Mad1:Mad2 complex is responsible for the recruit-
ment of Mad2DC to kinetochores, Alexa-Mad2DC bound
the recombinant Mad1:Mad2 complex indistinguishably
from Alexa-Mad2wt (Figures 4A–4B). Because Mad2DC is
unable to bind Mad1, this result shows that the binding
of O-Mad2 to the Mad1:Mad2 complex does not imply
direct binding to Mad1.
Mad2DC cycled on the recombinant Mad1:Mad2 com-
plex with slightly faster dynamics relative to Mad2wt
(Figure 4C and Table 1J and 1K), possibly reflecting
a marginal contribution of the O-Mad2 C-terminal tail,
which is partly deleted in Mad2DC, to formation of the
O-Mad2:C-Mad2 complex. Consistent with these results
in vitro, Alexa-Mad2DC introduced in mitotic PtK1 cells
by microinjection cycled at kinetochores with kinetics
that were similar to those previously observed when
Mad2wt was used in vivo [5, 6], but, as for the in vitro
case, were slightly faster relative to Mad2wt (Figure 4D
and Table 1E).
The overexpression of Mad2DC has a dominant-nega-
tive effect on the SAC [19, 20, 22, 23]. This effect is likely
due to the fact that Mad2DC binds C-Mad2 and compet-
itively inhibits binding of O-Mad2wt, preventing Mad2wt
from reaching Cdc20. To illustrate this, we bound CFP-
Mad2 to immobilized Mad1:C-Mad2 (Figure 5A, upper
panel). We then added a 2-fold excess of unlabeled
Mad2DC. This readily displaced CFP-Mad2 from the
beads (Figure 5A, lower panel).
Unlike Mad2DC, which deregulates the SAC nonphy-
siologically, the Mad2 binding protein p31comet (previ-
ously CMT2) is a physiological negative regulator of
the SAC [24, 25]. The observation that p31comet binds
selectively to C-Mad2 and does not bind O-Mad2
prompted the suggestion that p31comet might prevent
C-Mad2 from sequestering Cdc20 [25]. In contradiction
to this expectation, however, p31comet was found to bind
tightly to the Cdc20:C-Mad2 complex without affecting
its stability [25], so p31comet must function in a different
way.
Because C-Mad2 is present both in the Mad1:C-Mad2
and in the Cdc20:C-Mad2 complexes, p31comet, whichhas been previously shown to bind Cdc20:C-Mad2
[25], is also predicted to bind Mad1:C-Mad2. Indeed,
CFP-p31comet formed a tight complex with Mad1:C-
Mad2 (Figures 5B and 5C), whose dissociation constant
(KD) by ITC wasw25 nM (Table 2B). In agreement with its
tight binding, CFP-p31comet cycled on the Mad1:C-Mad2
complex with a half-time of recovery of 20 s, indicative of
a slower rate of dissociation relative tow4 s half-life of
Mad2. The percent recovery was w90% (Figure 5D
and Table 1L).
The Mad2 template model [19, 26–28] suggests an
alternative hypothesis for understanding the function
of p31comet. The model proposes that the interaction be-
tween O-Mad2 and C-Mad2 activates O-Mad2 for Cdc20
binding and is therefore critical for the SAC. Interfering
with this interaction will depress the SAC, as illustrated
by the dominant-negative effects of Mad2DC. Thus, we
asked whether binding of p31comet to C-Mad2 might in-
terfere with the binding of O-Mad2, as is the case for
Mad2DC. Beads containing immobilized Mad1:C-Mad2
became brightly fluorescent in a medium containing
CFP-Mad2 (Figure 5E, upper panel). Shortly after the ad-
dition of an equimolar amount of unlabeled p31comet, the
fluorescence of CFP-Mad2 became almost entirely dis-
placed from the beads (Figure 5E, lower panel), showing
that p31comet binds C-Mad2 competitively with O-Mad2.
Thus, the effects of p31comet are essentially identical to
those observed with Mad2DC, whose expression abro-
gates the SAC.
Cdc20 cycles rapidly at kinetochores [5–8]. Whether
this cycle reflects its capture by Mad2 is currently un-
clear. Conversely, it is unknown whether the Mad2 cycle
on kinetochores is influenced by Cdc20, the protein to
which Mad2 is expected to bind at kinetochores. In
this respect, it is interesting to note that Mad2DC, which
does not bind Cdc20 [19, 21], cycled on C-Mad2 in vitro
and in vivo with a turnover rate similar to that of Mad2wt
(Table 1D, 1E, 1J, and 1K and Figure 4). This implies that
Cdc20 does not influence the turnover rate of kineto-
chore Mad2, suggesting that Mad2 is released from ki-
netochores before it binds Cdc20. An alternative expla-
nation, however, is that only a small fraction of O-Mad2
cycling on Mad1:C-Mad2 at kinetochores is removed by
Cdc20, too small to be observed in the Mad2 FRAP
curves in vivo.
To shed light on this issue, we developed an imple-
mentation of our recruitment assay allowing continuous
imaging of a surface containing immobilized Mad1:C-
Mad2 while being perfused with a solute. Biotinylated
nonfluorescent Mad1:C-Mad2 was immobilized on the
bottom surface of a flow cell connected to a peristaltic
pump. CFP-Mad2 was injected, and the flow was
stopped to allow equilibration. CFP-Mad2 bound readily
to the surface containing the Mad1:C-Mad2 receptor. If(E) We speculate that the recruitment of the Mad1:C-Mad2 complex to an unattached kinetochore results in the inactivation of p31comet and its
fast release from kinetochores. Note that p31comet may undergo a continuous cycle of inactivation at unattached kinetochores similar to the
Mad2 activation cycle. An unknown kinetochore function (green ball with question mark) inactivates p31comet.
(F) Cytosolic Mad2 has the O-Mad2 conformation [19, 20]. The Mad1:C-Mad2 complex recruits O-Mad2 to kinetochores, and O-Mad2 is con-
verted into C-Mad2 bound to Cdc20. Mad2:Cdc20 is a structural copy of Mad1:Mad2, because Mad1 and Cdc20 share a Mad2 binding motif,
and Mad2 adopts the same C-Mad2 conformation in these complexes. The ‘‘Mad2 template’’ model [19] predicts that C-Mad2:Cdc20 is a struc-
tural equivalent of Mad1:Mad2 and converts more O-Mad2 into Cdc20-bound C-Mad2, possibly creating a positive feedback module for ampli-
fication of the SAC signal.
(G) After microtubule attachment, Dynein removes Mad1:C-Mad2 from kinetochores [10]. Mad1:Mad2 is thus separated from the kinetochore
function that inactivates p31comet. This eventually leads to the reactivation of p31comet, which acts as a ‘‘screen’’ that interposes itself.
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the Cdc20111–138 synthetic peptide, CFP-Mad2 did not
accumulate on the surface, confirming that binding is
specific for O-Mad2 (Figure 6A). To assess the dynamic
properties of Mad2 in this new system, we performed
a FRAP experiment similar to that shown in Figure 3B.
The half-time and fraction of recovery were very similar
to those obtained on beads (Figure 6B and Table 1N).
Toassesswhether Cdc20 accelerates the removal ofO-
Mad2 from the Mad1:C-Mad2 complex, we carried out an
‘‘off rate’’ experiment (Figure 6C). CFP-Mad2 (2 mM) was
equilibrated on the immobilized Mad1:Mad2 complex.
We monitored the dissociation of CFP-Mad2 from the
Mad1:C-Mad2 surface while injecting into the chamber
a solution containing a 20-fold excess of dark O-Mad2DC
(which binds C-Mad2; identical results were obtained
with dark Mad2wt, data not shown) to prevent CFP-
Mad2 re binding to Mad1:Mad2. A plot of the time course
of dissociation of CFP-Mad2 from Mad1:Mad2 displayed
a single exponential decay with a half-time of 4.9 s,
slightly longer than but in very good agreement with
the values determined by FRAP (Figure 6C, data not
shown, and Table 1O and 1P). Next, we repeated this ex-
periment after adding Cdc20 (at 40 mM) together with the
same excess of dark O-Mad2DC. The dissociation curve
was fitted with a single exponential function with a half-
time of dissociation essentially identical to that mea-
sured in the absence of Cdc20 (Figure 6D and Table
1Q). These results indicate that Cdc20 does not influence
the turnover of kinetochore Mad2, at least in the absence
of a Cdc20 binding site near the Mad1:C-Mad2 complex.
Discussion
Our in vitro FRAP analysis recapitulates faithfully the re-
sults of previous FRAP analyses of Mad2 carried out in
living cells [5–7]. The analysis provides a straightforward
explanation of the differences in percent recoveries be-
tween experiments in which transient expression or pro-
tein injection of fluorescent Mad2 was used, reporting
near to full recovery of kinetochore Mad2 fluorescence
[5, 6], as opposed to experiments using stable YFP-
Mad2 expression and reporting 50% recovery [7]. The
most likely explanation of these discrepancies is that
the stability of the Mad1:C-Mad2 complex prevents
the binding of the fluorescent Mad2 species to Mad1,
unless a long-term expression strategy is adopted, as
was the case for the experiments using stable YFP-
Mad2 cell lines. This interpretation is confirmed by the
fact that the percent recovery of Alexa-Mad2DC injected
into PtK1 cells is also near 100% (Figure 4 and Table 1E),
as it is for Alexa-Mad2wt [5, 6]. Because Mad2DC is un-
able to bind Mad1 whereas Mad2wt is in principle able
to do it, the fact that both constructs provide the same
fraction of recovery suggests that there is not enough
time for fluorescent Mad2wt to bind Mad1 in these exper-
iments. Consistent with this prediction, if the FRAP ex-
periment in vitro was carried out with unlabeled Mad1:
Mad2 complex, near to 90% recovery was observed
(Figure 3B and Table 1G). This underscores the accu-
racy with which in vitro FRAP might provide detailed mo-
lecular accounts of dynamic live-cell measurements.
So far, the studies in living cells have reported some-
what different half-times of recovery, ranging between6 and 25 s (Table 1A–1D). Different camera acquisition
rates, sensitivities, and phototoxicity might all affect
the initial part of the recovery curve and provide some-
what different accounts of the times of recovery. In vitro,
we have consistently measured a half-time ofw3–5 s for
the Mad2 cycle (Table 1). This value is not more dissimilar
from the in vivo data than the in vivo measurements
among themselves. At present, we are unable to provide
a certain explanation for the observed discrepancy. We
note that it is possible that the slightly faster half-times
observed in vitro might reflect modulations of the affinity
of the interaction of the Mad1:C-Mad2 receptor for
O-Mad2 in vivo. In particular, a decreased half-time
(that is, a faster koff) implies (assuming an identical kon)
a decrease in the affinity of the interaction. It is possible
that additional interactions, such as for instance addi-
tional van der Waals contacts or additional hydrogen
bonds, provide an increased binding energy to the inter-
action. If existing, however, these effects must be mini-
mal because a 2- to 5-fold change in koff would only
predict a linear 2- to 5-fold change in the KD of the inter-
action. We also note that in cellular FRAP experiments
carried out so far, the fluorescent species coexisted
with endogenous nonfluorescent molecules. Thus, dark
endogenous molecules might compete with fluorescent
ones so that the apparent recovery will appear slower
than it would be in the absence of dark competitors.
Our results show unequivocally that the Mad1:C-
Mad2 complex does not dissociate during mitosis [7,
19]. The implication of this is that the two pools of
Mad2, the C-Mad2 pool bound to Mad1 and the cyto-
solic O-Mad2 pool destined to Cdc20, are distinct and
nonexchanging. Furthermore, this implies that the mole-
cules of Mad2 eventually destined to bind Cdc20 are
drafted exclusively from the cytosolic pool. The interac-
tion of these two genetically identical but conformation-
ally dissimilar pools in the O-Mad2:C-Mad2 complex is
a striking characterizing element of the Mad2 check-
point and bears clear resemblances—in addition to im-
portant differences—with prion proteins [29].
Our experiments also suggest that Cdc20 does not in-
fluence the rate of dissociation of ‘‘external’’ Mad2 from
its complex with Mad1:C-Mad2 (Figure 6). A possible ca-
veat with these experiments is that they were carried out
with a short segment of Cdc20, and we cannot exclude
that the missing segments of Cdc20 are important to ac-
celerate the dissociation of Mad2 from the Mad1:Mad2
complex. Future mechanistic studies on how the inter-
action of O-Mad2 with C-Mad2 fosters the interaction
with Cdc20 will have to address the actual conformation
of Mad2 dissociating from Mad1:Mad2. For this, we en-
vision that a real-time sensor of Mad2 conformation will
need to be developed.
Although Mad2 is able to bind Cdc20 in vitro in the ab-
sence of other proteins, the interaction is slow. For in-
stance, the binding of O-Mad2 to a synthetic peptide en-
compassing the Cdc20 sequence has an association
rate (kon) in the range of 10
2 M21s21 (M.V. and A.M., un-
published data). A slow rate of association is expected if
one considers the extent of the conformational change
O-Mad2 needs to undergo to bind Cdc20 turning into
C-Mad2. We suspect that the significance of the interac-
tion of O-Mad2 with C-Mad2 is to accelerate this struc-
tural conversion, possibly explaining the catalytic role
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765played by unattached kinetochores (i.e., Mad1:C-Mad2)
in generating the checkpoint signal.
It is also intriguing that the intrinsic properties of the
interaction between the two pools of Mad2 and its regu-
lation by p31comet appear to be largely sufficient for ex-
plaining the kinetochore cycle of Mad2. Our results de-
lineate a model predicting that kinetochores cause the
inactivation of p31comet and its release from Mad1:
C-Mad2 to allow kinetochore recruitment of O-Mad2
(Figures 6E–6G). The latter might be modified at kineto-
chores and released in an activated form that binds rap-
idly to Cdc20. Microtubule attachment results in the de-
pletion of Mad1 and Mad2 from kinetochores [10], and
this may coincide with the reactivation of p31comet and
subsequent inhibition of the O-Mad2:C-Mad2 interac-
tion. The ‘‘Mad2 template’’ model predicts a direct cata-
lytic role of C-Mad2 on the transformation of O-Mad2 to
C-Mad2 bound to Cdc20. Testing this prediction is
clearly essential for validating the model.
Conclusions
A proper understanding of the molecular network re-
sponsible for the spindle checkpoint requires a systems
approach, based upon law of mass action and mathe-
matical modeling [3, 4]. Oftentimes kinetic models are
underdetermined because experimental values for rate
constants and concentration are lacking. In vitro FRAP
and the other approaches reported here can contribute
to solving this major shortcoming of the modeling ap-
proach. In particular, we show in Supplemental Experi-
mental Procedures that combining in vitro FRAP with
a measure of KD allows the estimation of both kinetic
parameters (kon and koff) of an interaction. The proce-
dure is completely general and may be extended to
the study of virtually any macromolecular interaction.
Experimental Procedures
Protein Expression, Covalent Modifications of Proteins, and
Immunoprecipitations
Readers are referred to the Supplemental Experimental Procedures
section in the Supplemental Data.
In Vitro FRAP, Beads Implementation
Agarose beads with immobilized streptavidin (SIGMA, S1638) were
washed and equilibrated in PBS. Purified biotin-Mad1:CFP-Mad2
or biotin-Mad1:Mad2 were added at streptavidn:biotin ratio
of w32:1 and incubated for 1 hr at 4ºC. Beads with immobilized
Mad1:Mad2 were washed with PBS and stored at 280ºC until use.
FRAP measurements were performed on a Leica TCS SP2 confocal
microscope equipped with a 633/1.40 (OIL CS HC3PL APO) ob-
jective lens (Leica). Streptavidin-agarose beads containing w10
pmoles of immobilized Mad1/Mad2 core complexes were typically
mixed in a chambered coverglass well (Lab-Tek II) with 1500 pmoles
external ligand (Mad2 or p31comet) in a final volume of 100 ml PBS,
yielding molar concentrations of 0.1 mM and 15 mM, respectively. Ex-
ternal ligand concentrations of 15 mM and above were found to sat-
urate kinetics and to yield reproducible results. Imaging was con-
trolled by Leica Confocal Software (v. 2.61), and photobleaching
was carried out with the 488 nm line (Alexa-488) and the 458 nm
line (CFP) of an Ar/ArKr laser at 20 mW. An area with an approximate
diameter of 10 mm at the edge of a bead was bleached, and images
were collected with a temporal resolution of 115 ms between frames.
ImageJ software was used to calculate mean pixel intensities of
bleached areas with time, and the values were exported to an Excel
spreadsheet. Recovery percentage was taken as the final average
plateau intensity (FN) minus the fluorescence immediately after pho-
tobleaching (F0), all divided by the difference between prebleach (FI)and postbleach intensities [(FN 2 F0)/(FI 2 F0)]. The exponential ki-
netics of FRAP was analyzed by calculating the normalized unrecov-
ered fluorescence at each time-point [(FN2 Ft)/(FN2 F0)]. Recovery
half-times (t1/2) were calculated according to t1/2 = ln(2)/k, where k is
the time constant for a single-exponential recovery model [30]. For
ensuring possible artifact of photobleaching, the mean pixel intensi-
ties of the areas on the beads surrounding the bleached area were
monitored. If photobleaching occurred (<95% of original value at
the end of the experiment), or if the bead moved during analysis,
that particular measurement was excluded. All recovery measure-
ments displayed single exponential recovery kinetics.
In Vitro FRAP, Flat Surface
Twenty-five microliters flow cells (m-slide VI Flow-trough, Ibidi
GmbH, Munich, Germany) were coated with streptavidin essentially
as described [31]. The flow cell was injected with the following re-
agents in subsequent steps: 30 ml of 2.5 mg/ml Biotin-BSA (Pierce,
ImmunoPure Biotin-LC-BSA, #29130) dissolved in MilliQ water,
30 ml 1 mg/ml NeutrAvidin (Molecular Probes, A-2666) in TRIS-
EDTA buffer, and 30 ml 5 mg/ml BSA (A-9085 Sigma) in MilliQ water.
Each incubation was protracted for 30 min. After a washing step with
MilliQ water (53 chamber volume), the flow cell was equilibrated
with PBS. After this, 30 ml of 1 mM purified biotin-Mad1:Mad2 com-
plex in PBS was added and incubated for 30 min. Finally, the cells
were washed with 125 ml PBS. In vitro FRAP experiments were per-
formed with 2 mM external CFP-Mad2 equilibrated with immobilized
biotin-Mad1:Mad2. Photobleaching, data acquisition, and analysis
were performed as described above for the beads assay.
In Vivo FRAP
FRAP experiments on kinetochore-bound Alexa-Mad2DC and Alexa-
Mad2wt in PtK1 cells were carried out precisely as described before
[5, 6]. The quantification of these experiments is reported in Table 1.
Dissociation Rates
Imaging of dissociation experiments was carried out with a temporal
resolution of 0.15 s. The reaction was first driven to equilibration by
using 2 mM CFP-Mad2 on the immobilized biotin-Mad1:Mad2. Dis-
sociation was filmed while 50 ml of a 40-fold excess of O-Mad2
was injected at a flow rate of 25 ml/s. The images were analyzed
with ImageJ software, and the data were exported to an Excel
spreadsheet for analysis.
Relation of the FRAP Recovery-Rate Constant to koff and
Estimation of kon
Readers are referred to the Supplemental Experimental Procedures
in the Supplemental Data.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures
and two figures and are available with this article online at: http://
www.current-biology.com/cgi/content/full/16/8/755/DC1/.
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